Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Lymphoid 2

Conditions

Multiple Myeloma 430Neoplasms, Plasma Cell 58Recurrence 33Smoldering Multiple Myeloma 17Neoplasms 14Hematologic Diseases 11Immunoglobulin Light-chain Amyloidosis 8Leukemia, Plasma Cell 7Paraproteinemias 6Hematologic Neoplasms 6Amyloidosis 6Neoplasm, Residual 5Renal Insufficiency 4Plasmacytoma 4Lymphoma 4Disease Progression 4Disease 4Blood Protein Disorders 4Lymphoma, Non-Hodgkin 3POEMS Syndrome 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Corneal Diseases 2Bone Marrow Neoplasms 2Wilms Tumor 1Vitamin D Deficiency 1Vascular Diseases 1

Interventions

Lenalidomide 5Dexamethasone 4fludarabine phosphate 2daratumumab 2Whole-Body Irradiation 2Cyclophosphamide 2Calcium Dobesilate 2talquetamab 1selinexor 1ixazomib 1isatuximab 1fludarabine 1Transplantation, Autologous 1Sirolimus 1Rituximab 1Mycophenolic Acid 1Melphalan 1Bortezomib 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasm, Residual × Lenalidomide × Plasma cell × Clear all
NCT05690984 2026-03-16

EMAT

Medical College of Wisconsin

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT02389517 2026-01-22

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

University of Chicago

Phase 2 Completed
42 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Peking University People's Hospital

Phase NA Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Washington University School of Medicine

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡